{Reference Type}: Case Reports
{Title}: Cancer-Associated Thrombotic Microangiopathy: Literature Review and Report of Five Cases.
{Author}: Posado-Domínguez L;Chamorro AJ;Del Barco-Morillo E;Martín-Galache M;Bueno-Sacristán D;Fonseca-Sánchez E;Olivares-Hernández A;
{Journal}: Life (Basel)
{Volume}: 14
{Issue}: 7
{Year}: 2024 Jul 10
{Factor}: 3.251
{DOI}: 10.3390/life14070865
{Abstract}: Thrombotic microangiopathy (TMA) is an anatomopathological lesion mediated by endothelial dysfunction and characterized by the creation of microthrombi in small vessels. In patients with cancer, it may be due to toxicity secondary to chemotherapy, tumor embolization, or hematopoietic progenitor transplantation. Cancer-associated TMA is an underestimated entity that generally appears in the final stages of the disease, although it may also be the initial manifestation of an underlying cancer. Support treatment is necessary in all cases and, depending on the cause, different targeted therapies may be used. The prognosis is very poor. In this article we present a comprehensive review of the existing literature on the physiological mechanisms of cancer-associated TMA. Afterwards, five clinical cases will be presented of patients who developed TMA and were diagnosed in our Department in 2023. We present a discussion of the different causes that triggered the condition, the possible reasons behind the underestimation of this pathology, and the measures that may be adopted.